. 2010 Sep 10;29(4):581–594. doi: 10.1007/s10555-010-9248-x

Table 1.

Efficacy end points from upfront adjuvant trials comparing tamoxifen and aromatase inhibitors

Initial adjuvant trials	Endpoint	F/U (months)	HR for recurrence	P value
BIG 1-98 (letrozole)	TTDR	25.8 (PCA)	0.73^a	0.001
	TTDR	76 (MAA)	0.85^a	0.05
	DFS	25.8 (PCA)	0.81^a	0.003
	DFS	76 (MAA)	0.88^a	0.03
	OS	25.8 (PCA)	0.86^a	0.16
	OS	76 (MAA)	0.87^a	0.08
ATAC (anastrozole)	TTR	68	0.74^b	0.0002
	TTR	100	0.76^b	0.0001
	TTDR	68	0.84^b	0.06
	TTDR	100	0.84^b	0.022
	DFS	68	0.83^b	0.01
	DFS	100	0.85^b	0.003
	OS	68	0.97^b	0.7
	OS	100	0.97^b	0.7

Source: [11, 12, 15, 16]

ATAC arimidex, tamoxifen alone or in combination, BIG Breast International Group, DFS disease-free survival, HR hazard ratio, OS overall survival, MAA monotherapy arm analysis, PCA primary core analysis, TTDR time to distant recurrence, TTR time to recurrence

^aITT population

^bHR+ population